10q23.3 Loss of heterozygosity is higher in lymph node-positive (pT2-3, N+) versus lymph node-negative (pT2-3, N0) prostate cancer

Mark A. Rubin, Amy Gerstein, Kris Reid, David G. Bostwick, Liang Cheng, Ramon Parsons, Nickolas Papadopoulos

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Loss of heterozygosity (LOH) in the region of 10q23.3 has been associated with multiple tumors, including glioblastoma multiforme, melanoma, endometrial carcinoma, and prostate carcinoma. The tumor suppressor gene, PTEN/MMAC1, is also located in this region, and, in addition to other tumor types (eg, glioblastoma multiforme, endometrial, and melanoma), PTEN/MMAC1 mutations have been found in prostate cancer cell lines, xenografts, and hormone refractory prostate cancer tissue specimens. The aim of this study was to evaluate LOH at 10q23.3 as a marker of cancer progression in node- positive prostate cancer. Genetic alterations in the region of 10q23.3 were assessed in 23 node-positive (pT2-3, N+) and 44 node-negative prostate (pT2- 3, N0) cancers with D10S532, D10S1687, D10S541, and D10S583 flanking polymorphic genetic markers; PTENCA, a genetic marker within PTEN/MMAC1, was also tested. Using DNA from paired normal and microdissected tumor samples, LOH at microsatellite loci was determined after polymerase chain reaction amplification. LOH in at least 1 marker was identified in 14% (6 of 44) of lymph node-negative and 43% (10 of 23) of lymph node-positive prostate cancers (chi-square test, P = .007). This increase in genetic alterations in node-positive prostate cancer suggests that 10q23.3 is a marker for metastatic progression. Copyright (C) 2000 by W. B. Saunders Company.

Original languageEnglish (US)
Pages (from-to)504-508
Number of pages5
JournalHuman Pathology
Volume31
Issue number4
StatePublished - 2000
Externally publishedYes

Fingerprint

Loss of Heterozygosity
Prostatic Neoplasms
Lymph Nodes
Neoplasms
Glioblastoma
Genetic Markers
Prostate
Melanoma
Chi-Square Distribution
Endometrial Neoplasms
Tumor Suppressor Genes
Heterografts
Microsatellite Repeats
Hormones
Carcinoma
Cell Line
Polymerase Chain Reaction
Mutation
DNA

Keywords

  • 10q23
  • Chromosome 10
  • Prostate cancer
  • PTEN/MMAC1

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Rubin, M. A., Gerstein, A., Reid, K., Bostwick, D. G., Cheng, L., Parsons, R., & Papadopoulos, N. (2000). 10q23.3 Loss of heterozygosity is higher in lymph node-positive (pT2-3, N+) versus lymph node-negative (pT2-3, N0) prostate cancer. Human Pathology, 31(4), 504-508.

10q23.3 Loss of heterozygosity is higher in lymph node-positive (pT2-3, N+) versus lymph node-negative (pT2-3, N0) prostate cancer. / Rubin, Mark A.; Gerstein, Amy; Reid, Kris; Bostwick, David G.; Cheng, Liang; Parsons, Ramon; Papadopoulos, Nickolas.

In: Human Pathology, Vol. 31, No. 4, 2000, p. 504-508.

Research output: Contribution to journalArticle

Rubin, MA, Gerstein, A, Reid, K, Bostwick, DG, Cheng, L, Parsons, R & Papadopoulos, N 2000, '10q23.3 Loss of heterozygosity is higher in lymph node-positive (pT2-3, N+) versus lymph node-negative (pT2-3, N0) prostate cancer', Human Pathology, vol. 31, no. 4, pp. 504-508.
Rubin, Mark A. ; Gerstein, Amy ; Reid, Kris ; Bostwick, David G. ; Cheng, Liang ; Parsons, Ramon ; Papadopoulos, Nickolas. / 10q23.3 Loss of heterozygosity is higher in lymph node-positive (pT2-3, N+) versus lymph node-negative (pT2-3, N0) prostate cancer. In: Human Pathology. 2000 ; Vol. 31, No. 4. pp. 504-508.
@article{0491f0c44a674258b5f1de095ce4fc75,
title = "10q23.3 Loss of heterozygosity is higher in lymph node-positive (pT2-3, N+) versus lymph node-negative (pT2-3, N0) prostate cancer",
abstract = "Loss of heterozygosity (LOH) in the region of 10q23.3 has been associated with multiple tumors, including glioblastoma multiforme, melanoma, endometrial carcinoma, and prostate carcinoma. The tumor suppressor gene, PTEN/MMAC1, is also located in this region, and, in addition to other tumor types (eg, glioblastoma multiforme, endometrial, and melanoma), PTEN/MMAC1 mutations have been found in prostate cancer cell lines, xenografts, and hormone refractory prostate cancer tissue specimens. The aim of this study was to evaluate LOH at 10q23.3 as a marker of cancer progression in node- positive prostate cancer. Genetic alterations in the region of 10q23.3 were assessed in 23 node-positive (pT2-3, N+) and 44 node-negative prostate (pT2- 3, N0) cancers with D10S532, D10S1687, D10S541, and D10S583 flanking polymorphic genetic markers; PTENCA, a genetic marker within PTEN/MMAC1, was also tested. Using DNA from paired normal and microdissected tumor samples, LOH at microsatellite loci was determined after polymerase chain reaction amplification. LOH in at least 1 marker was identified in 14{\%} (6 of 44) of lymph node-negative and 43{\%} (10 of 23) of lymph node-positive prostate cancers (chi-square test, P = .007). This increase in genetic alterations in node-positive prostate cancer suggests that 10q23.3 is a marker for metastatic progression. Copyright (C) 2000 by W. B. Saunders Company.",
keywords = "10q23, Chromosome 10, Prostate cancer, PTEN/MMAC1",
author = "Rubin, {Mark A.} and Amy Gerstein and Kris Reid and Bostwick, {David G.} and Liang Cheng and Ramon Parsons and Nickolas Papadopoulos",
year = "2000",
language = "English (US)",
volume = "31",
pages = "504--508",
journal = "Human Pathology",
issn = "0046-8177",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - 10q23.3 Loss of heterozygosity is higher in lymph node-positive (pT2-3, N+) versus lymph node-negative (pT2-3, N0) prostate cancer

AU - Rubin, Mark A.

AU - Gerstein, Amy

AU - Reid, Kris

AU - Bostwick, David G.

AU - Cheng, Liang

AU - Parsons, Ramon

AU - Papadopoulos, Nickolas

PY - 2000

Y1 - 2000

N2 - Loss of heterozygosity (LOH) in the region of 10q23.3 has been associated with multiple tumors, including glioblastoma multiforme, melanoma, endometrial carcinoma, and prostate carcinoma. The tumor suppressor gene, PTEN/MMAC1, is also located in this region, and, in addition to other tumor types (eg, glioblastoma multiforme, endometrial, and melanoma), PTEN/MMAC1 mutations have been found in prostate cancer cell lines, xenografts, and hormone refractory prostate cancer tissue specimens. The aim of this study was to evaluate LOH at 10q23.3 as a marker of cancer progression in node- positive prostate cancer. Genetic alterations in the region of 10q23.3 were assessed in 23 node-positive (pT2-3, N+) and 44 node-negative prostate (pT2- 3, N0) cancers with D10S532, D10S1687, D10S541, and D10S583 flanking polymorphic genetic markers; PTENCA, a genetic marker within PTEN/MMAC1, was also tested. Using DNA from paired normal and microdissected tumor samples, LOH at microsatellite loci was determined after polymerase chain reaction amplification. LOH in at least 1 marker was identified in 14% (6 of 44) of lymph node-negative and 43% (10 of 23) of lymph node-positive prostate cancers (chi-square test, P = .007). This increase in genetic alterations in node-positive prostate cancer suggests that 10q23.3 is a marker for metastatic progression. Copyright (C) 2000 by W. B. Saunders Company.

AB - Loss of heterozygosity (LOH) in the region of 10q23.3 has been associated with multiple tumors, including glioblastoma multiforme, melanoma, endometrial carcinoma, and prostate carcinoma. The tumor suppressor gene, PTEN/MMAC1, is also located in this region, and, in addition to other tumor types (eg, glioblastoma multiforme, endometrial, and melanoma), PTEN/MMAC1 mutations have been found in prostate cancer cell lines, xenografts, and hormone refractory prostate cancer tissue specimens. The aim of this study was to evaluate LOH at 10q23.3 as a marker of cancer progression in node- positive prostate cancer. Genetic alterations in the region of 10q23.3 were assessed in 23 node-positive (pT2-3, N+) and 44 node-negative prostate (pT2- 3, N0) cancers with D10S532, D10S1687, D10S541, and D10S583 flanking polymorphic genetic markers; PTENCA, a genetic marker within PTEN/MMAC1, was also tested. Using DNA from paired normal and microdissected tumor samples, LOH at microsatellite loci was determined after polymerase chain reaction amplification. LOH in at least 1 marker was identified in 14% (6 of 44) of lymph node-negative and 43% (10 of 23) of lymph node-positive prostate cancers (chi-square test, P = .007). This increase in genetic alterations in node-positive prostate cancer suggests that 10q23.3 is a marker for metastatic progression. Copyright (C) 2000 by W. B. Saunders Company.

KW - 10q23

KW - Chromosome 10

KW - Prostate cancer

KW - PTEN/MMAC1

UR - http://www.scopus.com/inward/record.url?scp=0034075812&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034075812&partnerID=8YFLogxK

M3 - Article

VL - 31

SP - 504

EP - 508

JO - Human Pathology

JF - Human Pathology

SN - 0046-8177

IS - 4

ER -